我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 日内瓦医学教育与研究基金会
  • ICMJE
分享此页面

抽象的

A Shield against Rift Valley Fever: Monoclonal Antibody Strikes the Vulnerable Site

Christian Schindler

Rift Valley Fever (RVF) is a severe viral disease with significant public health and agricultural implications. In this article, we highlight a groundbreaking discovery—a monoclonal antibody that specifically targets a vulnerable site on the surface of the Rift Valley Fever virus. Through innovative research methods, scientists identified this vulnerable site crucial for viral entry and replication. The monoclonal antibody, designed to bind tightly to the site, acts as a shield, preventing viral attachment to host cells and neutralizing the virus. This breakthrough has immense potential for both therapeutic and preventive interventions against RVF. However, further research, clinical trials, and large-scale production are necessary to fully harness the potential of this monoclonal antibody. Nevertheless, this discovery represents a significant advancement in our ability to combat Rift Valley Fever and offers hope for improved disease control strategies.